Case Report

Identification of Novel Mutations in Spatacsin and Apolipoprotein B Genes in a Patient with Spastic Paraplegia and Hypobetalipoproteinemia

Leema Reddy Peddareddyari and Raji P. Grewal

1. Introduction

Hereditary spastic paraplegias (HSPs) are a genetically heterogeneous group of neurodegenerative disorders with autosomal dominant, recessive, or an X-linked pattern of inheritance. Clinically they can be classified as pure (or uncomplicated) form or the complicated form of HSP where spasticity may be associated with a combination of neurological or nonneurological manifestations. These can include cerebellar ataxia, dysarthria, mental retardation, optic atrophy, retinitis pigmentosa, hearing loss, a thin corpus callosum, or peripheral neuropathy. HSP can also be genetically classified depending on their specific locus which at present ranges from SPG1 to SPG72 (http://neuromuscular.wustl.edu/spinal/fsp.html).

Familial hypobetalipoproteinemia (FHBL) is an autosomal dominant condition characterized by low plasma concentrations of total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B (apoB). Mutations in several different genes can cause hypobetalipoproteinemia, the most common of which are a result of truncating mutations in the APOB gene [1].

Several different mechanisms have been proposed regarding the pathogenesis of HSP including defective subcellular transportation, mitochondrial malfunction, and increased oxidative stress. Most recently the identification of I088C > T (S363F) mutation in exon 5 of cytochrome P450-7BI in SPG5 disease locus provides a link between cholesterol metabolism and neuronal degeneration in HSPs [2]. The association of HSP with familial hypobetalipoproteinemia is rare and has been reported only once previously [3]. Although a disease causing mutation in this family was identified in the APOB gene, they were not able to identify the genetic cause of HSP.

We report a patient with HSP and associated hypobetalipoproteinemia in whom whole exome sequencing was performed to identify the disease causative mutation(s) after initial diagnostic testing for HSP was negative.
2. Case Presentation

This is a 30-year-old man who was well until the age of 13 years when he started tripping and falling. He was observed to be dragging his feet and developed a clumsy gait. These symptoms progressed and he started to use a cane at the age of 16, a walker at the age of 18, and, ultimately, a wheelchair at the age of 24 years. During this time period he had numerous neurological evaluations and was diagnosed with spastic paraparesis. He has had no associated complaints of pain, numbness, bowel or bladder symptoms, seizures, visual abnormalities, or vertigo. In the last few years, he has developed symptoms of dystarthritis speech and clumsiness of his upper extremities. He was diagnosed with attention deficit disorder and further evaluations showed IQ scores (Wechsler Intelligence Scale for Children) of 107 (verbal), 100 (performance), with an overall score of 103. He went on to complete high school and postsecondary education.

He is the product of a normal full term pregnancy and although both parents are of Italian origin, there is no consanguinity. There is no family history of any neurological disorder on either the paternal or maternal branches of the family. The patient has no siblings.

General physical examination revealed no abnormalities. Neurological examination performed showed a minimental status score of 30/30. His speech was dystarthric but otherwise the cranial nerve and sensory examinations were normal. The stretch reflexes were diffusely pathologically brisk and here had sustained clonus at the ankles with bilateral extensor responses. Motor examination revealed a marked hypertonia across all joints bilaterally. Both lower extremities were extended at the knee joint and very spastic. Power was full across all joints bilaterally. The patient could stand unassisted. A neurological examination was performed on both parents and revealed no abnormalities.

During the course of his medical care many investigations were performed and the following tests were either normal or negative: routine serum chemistries, cell count and differential, creatine phosphokinase, renal and thyroid function studies, and serology for HTLV1.

In addition, magnetic resonance imaging studies of his spinal cord and brain were normal. An electromyography indicated no evidence of neuropathy or myopathy.

A lipid profile of the patient had been performed as part of routine screening and was abnormal. Subsequently, lipid profiles of both parents were performed (Table 1).

3. Genetic Testing

All of the genetic investigations performed on this patient and his family members were done after informed consent was obtained following local IRB policies and procedures. Prior genetic testing performed at a number of commercial laboratories was negative for specific genes tested, including DYT1, SPG3A, SPG4, and NIPA1. However, the spastic paraplegia II (SPGII) gene had not been tested. We elected to perform whole exome sequencing through a commercial lab using Illumina HiSeq 2000 platform; sequence capture was done using Agilent SureSelect. The paired-end raw reads were aligned to the hg19 (USCS version) human genome reference and variant list compiled. The raw variant list was analyzed for variants in the known SPG genes and since the patient’s lipid profile was consistent with hypobetalipoproteinemia, the variants in APOB gene were also analyzed.

The nucleotide level variant analysis of SPG genes revealed two novel variants on chromosome 15 located in SPGII gene. Both of the single nucleotide polymorphisms (SNPs) were reconfirmed in the patient by Sanger sequencing (Figure 1). One variant at genomic position, 44905652, resulted in a heterozygous c.3337G > A change in exon 6 (ENSE0000183238, NM_025137). This change results in premature truncation of the spatacsin protein p.W441X (Figure 1(a)). The second variant at genomic position 44943823 results in a c.3121C > T change in the exon 17 (ENSE000001287244, NM_025137) of the SPGII gene also resulting in premature truncation of the spatacsin protein p.R1041X (Figure 1(b)).

The nucleotide level variant analysis of APOB gene on chromosome 2 revealed two SNPs that were reconfirmed by Sanger sequencing (Figure 2). A previously described change at genomic position 21238413 that causes c.3337G > C change in exon 22 (ENSE00000542198, NM_000384), resulting in a missense mutation from substitution of amino acid, p.D1113H (Figure 2(a)). A novel SNP was also identified, a G to T change at genomic position 21228407. This heterozygous c.11333C > A variant in the exon 26 (ENSE00001183453, NM_000384) results in a stop codon leading to premature truncation of the protein p.S3778X (Figure 2(b)).

The patient is a compound heterozygous for two truncating mutations in the SPGII gene. Sanger sequencing of the exons containing these individual SNPs on DNA obtained from his parents indicates that the patient has inherited the p.W441X mutation from the mother and p.R1041X mutation from the father (Figure 3). The parents were also tested for

### Table 1: Lipid profile values of the patient and his parents.

| Lipid profile     | Patient | Mother | Father | Normal range |
|-------------------|---------|--------|--------|--------------|
| Total cholesterol | 82 mg/dL| 214 mg/dL| 117 mg/dL| <200 mg/dL |
| Triglycerides     | 104 mg/dL| 163 mg/dL| 120 mg/dL| <150 mg/dL |
| HDL               | 39 mg/dL| 51 mg/dL| 50 mg/dL| ≤40 mg/dL   |
| VLDL              | 17 mg/dL| 28 mg/dL| 17 mg/dL| <30 mg/dL   |
| LDL               | 25 mg/dL| 135 mg/dL| 50 mg/dL| <130 mg/dL  |
| apoB-100-cal      | 41 mg/dL| 109 mg/dL| 53 mg/dL| <109 mg/dL  |
the \textit{APOB} mutations and no mutations were detected in the mother. However, analysis of the paternal DNA shows the presence of both \textit{APOB} variants (Figure 3).

4. Discussion

Spastic paraplegia 11 (SPG11) is an autosomal recessive disorder caused by loss of function mutations in the \textit{spatacsin} (SPG11) gene on chromosome 15q21.1. This patient’s phenotype is consistent with that described in previously reported patients with genetically confirmed SPG11 (http://neuromuscular.wustl.edu/spinal/fsp.html#spgmu). There are 98 pathogenic/likely pathogenic SNPs that have been reported (http://www.ncbi.nlm.nih.gov/clinvar/). Our patient inherited two losses of function mutations, one from each parent. Both of these mutations are novel and result in premature truncation of the protein strongly suggesting that they are disease producing mutations causing HSP.

The \textit{APOB} gene is translated into both apoB-100 and apoB-48 proteins. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA → UAA), resulting in a stop codon producing early termination. The majority of reported \textit{APOB} mutations result in premature truncation of the protein. In heterozygous \textit{APOB} mutation, the normal apoB-100 product is produced at a lower rate while truncated apoB is cleared too rapidly resulting in the low apoB-100 levels [4]. Nonsynonymous, nontruncating \textit{APOB} mutations have also been reported [5, 6]. It was reported that a nontruncated mutant protein causes secretion impairment compared with the normal secretion of the mutant truncated proteins [7]. All of the previously reported nontruncating mutations are observed in residues 292–593.

Heterozygotes for FHBL have less than half-normal LDL-cholesterol and apoB concentrations, whereas homozygotes have extremely low or undetectable LDL-cholesterol and apoB levels. Both the father and the son have variants in exons 22 and 26. The exon 22 variant causes a substitution of aspartic acid at position 1113 with histidine and affects both apoB-100 and apoB-48. This SNP has been reported in
the 1000-genome project with a minor allele frequency of G = 0.0037 and this change is predicted to be damaging to the protein by both Sift (score 0.02) and PolyPhen (score 0.999) analysis (http://www.ensembl.org/index.html, rs12713844). This variant does not involve the N-terminal β1 domain (residues 1–930) of the protein which is important for effective secretion and in subpopulation of Utah residents (CEPH) with Northern and Western European ancestry the frequency of allele G is reported to be as high as 2%. Therefore APOB p.D1113H may not be a disease producing variant. The exon 26 (ENSE00001183453, NM_000384) encodes amino acids 1406 to 3931. The exon 26 variant, 3778 (TCA → TAA), inherited by the patient from his father results in a stop codon leading to premature truncation of the protein p.S3778X. Therefore, it is more likely that the disease causing mutation in the father and son is this exon 26 variant which does not affect apoB-48 but does cause premature truncation of the apoB-100 at residue 3778. In previous reports of heterozygotes for point mutations located in the exon 26 of the APOB gene it was found that the clinical manifestations of FHBL are dependent on the size of the resultant truncated apoB [7]. This variant likely accounts for the low LDL-cholesterol, total cholesterol, and apoB-100 observed in the father and son.

When the patient was first encountered, similar to the previously reported family [3], it was hypothesized that there may be connection between the abnormal cholesterol profile and spasticity. However, the genetic analysis performed indicates that these are disparate clinical features.

This case provides support for the value of whole exome sequencing as a diagnostic tool for identification of mutations in conditions where the commercial testings were negative. We were able to identify the genetic cause for hereditary spastic paraplegia and hypobetalipoproteinemia in this patient presenting with a rare combination of autosomal recessive progressive spastic paraparesis and autosomal dominant hypobetalipoproteinemia with normal triglycerides.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors thank all members of this family for their cooperation and are grateful for the support from the Neuro-Genetics Institute, Sharon Hill, PA, and the Neurogenetics Foundation, NJ.

References

[1] P. Tarugi and M. Averna, “Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum,” Advances in Clinical Chemistry, vol. 54, pp. 81–107, 2011.

[2] M. K. Tsatsoussidou, K. Ouahchi, T. T. Warner et al., “Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration,” The American Journal of Human Genetics, vol. 82, no. 2, pp. 510–515, 2008.

[3] A. J. Hooper, B. Akinci, A. Comlekci, and J. R. Burnett, “Familial hypobetalipoproteinemia in a Turkish family with hereditary spastic paraplegia,” Clinica Chimica Acta, vol. 390, no. 1-2, pp. 152–155, 2008.

[4] G. Schonfeld, X. Lin, and P. Yue, “Familial hypobetalipoproteinemia: genetics and metabolism,” Cellular and Molecular Life Sciences, vol. 62, no. 12, pp. 1372–1378, 2005.

[5] J. R. Burnett, J. Shan, B. A. Miskie et al., “A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia,” The Journal of Biological Chemistry, vol. 278, no. 15, pp. 13442–13452, 2003.

[6] J. R. Burnett, S. Zhong, Z. G. Jiang et al., “Missense mutations in APOB within the β1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia,” The Journal of Biological Chemistry, vol. 282, no. 33, pp. 24270–24283, 2007.

[7] R. Martín-Morales, J. D. García-Díaz, P. Tarugi et al., “Familial hypobetalipoproteinemia: analysis of three Spanish cases with two new mutations in the APOB gene,” Gene, vol. 531, no. 1, pp. 92–96, 2013.